TY - JOUR
T1 - Clinical updates in mesenchymal stromal cell therapy for osteoarthritis treatment
AU - Im, Gun Il
N1 - Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - Introduction: Osteoarthritis (OA) is a common chronic musculoskeletal disease with heterogeneous clinical manifestations and variable responses to different treatments. Unfortunately, there is no effective disease modifying therapy at present that can alter the natural course of the disease. Cell therapy based on mesenchymal stromal cells (MSCs) may offer an attractive therapeutic option for OA with their multiple modes of action, particularly immune-regulatory and regenerative capacities. Areas covered: In this narrative review, updates on mode of action based on patient’s data, factors that can influence the efficacy of MSC treatment, current status in clinical application of MSCs as seen from randomized, controlled OA trials are introduced as well as the author’s perspectives in the future of MSCs as OA therapeutics. Expert opinion: Symptomatic relief is not sufficient to justify the high cost associated with culture-expanded stem cells. Its advantages and efficacy over simple and low risk/cost modalities should be seriously reevaluated. Also, as the short-term strategy, efforts should be made to lower the cost of MSC therapy. In the future, multiomics technology may help to predict that subgroup of patients who will favorably respond to stem cell treatment, which would enhance the cost effectiveness and therapeutic benefit of MSC therapy.
AB - Introduction: Osteoarthritis (OA) is a common chronic musculoskeletal disease with heterogeneous clinical manifestations and variable responses to different treatments. Unfortunately, there is no effective disease modifying therapy at present that can alter the natural course of the disease. Cell therapy based on mesenchymal stromal cells (MSCs) may offer an attractive therapeutic option for OA with their multiple modes of action, particularly immune-regulatory and regenerative capacities. Areas covered: In this narrative review, updates on mode of action based on patient’s data, factors that can influence the efficacy of MSC treatment, current status in clinical application of MSCs as seen from randomized, controlled OA trials are introduced as well as the author’s perspectives in the future of MSCs as OA therapeutics. Expert opinion: Symptomatic relief is not sufficient to justify the high cost associated with culture-expanded stem cells. Its advantages and efficacy over simple and low risk/cost modalities should be seriously reevaluated. Also, as the short-term strategy, efforts should be made to lower the cost of MSC therapy. In the future, multiomics technology may help to predict that subgroup of patients who will favorably respond to stem cell treatment, which would enhance the cost effectiveness and therapeutic benefit of MSC therapy.
KW - cell therapy
KW - clinical application
KW - mesenchymal stromal cell
KW - osteoarthritis
KW - regenerative medicine
UR - http://www.scopus.com/inward/record.url?scp=85213055908&partnerID=8YFLogxK
U2 - 10.1080/14712598.2024.2446612
DO - 10.1080/14712598.2024.2446612
M3 - Review article
AN - SCOPUS:85213055908
SN - 1471-2598
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
ER -